This website is intended for UK patients who have been prescribed Sogroya®▼ (somapacitan) or their carers.
Patient Resources
This website has been produced and funded by Novo Nordisk UK to provide information about Sogroya® ▼ (somapacitan) and is intended for UK patients prescribed the medication. The website is designed to provide a range of resources to support your use of Sogroya®.
This information does not replace the patient information leaflet, which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice.
This material is designed to be viewed digitally. It contains hyperlinks and videos which are viewable online only.
Adverse Event Reporting can be found at the bottom of this page.
In the list below, you can access the links to the Sogroya® Patient Information Leaflet, which can be found on the electronic Medicines Compendium (eMC)
Sogroya®▼ Patient Information Leaflet
- Sogroya® 10 mg/1.5 ml, solution for injection in pre-filled pen - Patient Information Leaflet
- Sogroya® 15 mg/1.5 ml, solution for injection in pre-filled pen - Patient Information Leaflet
USING SOGROYA®
Instructions on how to use Sogroya®
Please refer to the Patient Information Leaflet found in the product carton or online on the electronic Medicines Compendium (eMC) for further information on Sogroya®, including how to use the pre-filled pen, a full list of possible side effects, and warnings and precautions.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.
▼: This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
See yellowcard.mhra.gov.uk for how to report side effects.